Any current/future new fundraising through debt or equity?

There is no mention in the transcript about any current or future fundraising through debt or equity. The discussion primarily focuses on the $6.5 million capex funding for the dedicated API block, which is entirely funded by the innovator (Unicycive) with no financial outlay from Shilpa Medicare. No additional plans for capital raising through equity or debt are discussed during the call. The company appears focused on executing the existing manufacturing and supply agreements, along with milestone and licensing revenue.

Any current/future capex/capital investment/strategic investment?

Shilpa Medicare is setting up a dedicated API manufacturing block funded by their client (Unicycive Therapeutics) with a capex of approximately $6.5 million. This dedicated block is being created to ensure supply does not hamper existing deliveries and will be ready within the next year. The client is fully funding this capex; Shilpa is not contributing to this investment. The dedicated block will have capacity sufficient for supply requirements over the next 2-3 years. The funding and dedicated capacity demonstrate the strategic importance of this product and project to Shilpa. No a

Future growth expectations in sales/revenue/volumes?

The new API plant funded by the innovator will suffice supply for the next 2-3 years, indicating expected volume growth in that period. Binding orders currently include 5 million tablets by June 2025 and 15 million by December 2025, with multi-million tablets expected annually thereafter. Commercial supplies are set to start from Q1 2025, aligned with anticipated FDA approval within 10-12 months. Revenue includes a $10 million cumulative licensing fee expected mostly before product approval, plus additional sales revenue post-launch. EBITDA margin for this NCE molecule is expected abov

Future growth expectations in earnings/operating earnings/profits/EPS?

Shilpa Medicare's collaboration on the Oxylanthanum Carbonate (OLC) NCE molecule with Unicycive is expected to be a substantial revenue generator, with multimillion-dollar potential. The company expects over 50% EBITDA margins from this exclusive CDMO supply contract. Binding supply agreements involve supply of 5 million tablets by June 2025 and 15 million by December 2025, extending multi-year commercial supplies likely increasing revenues over several years. $10 million cumulative milestone payments are expected, mostly before NDA approval, followed by ongoing sales revenue post launch. The

Current/ Expected Orderbook/ Pending Orders?

Unicycive has placed binding orders of 5 million tablets to be delivered before June 2025 and 15 million tablets before December 2025. The binding agreement with Unicycive is for a term of four years, with multi-million tablet volumes expected each year beyond initial orders. For tail supply, there is an order of 15 million tablets to be supplied before December. The dedicated API manufacturing plant funded by Unicycive will suffice supply requirements for the next 2-3 years. Currently, supply is ongoing from existing blocks while a dedicated manufacturing block is being built, expected to be

Shilpa Medicare LtdQ1 FY25Pharmaceuticals & Biotechnology

Shilpa Medicare Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹876.2P/E: 60.2Market Cap: ₹17.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

N/A

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The new API plant funded by the innovator will suffice supply for the next 2-3 years, indicating expected volume growth in that period.
Binding orders currently include 5 million tablets by June 2025 and 15 million by December 2025, with multi-million tablets expected annually thereafter.
Commercial supplies are set to start from Q1 2025, aligned with anticipated FDA approval within 10-12 months.
Revenue includes a $10 million cumulative licensing fee expected mostly before product approval, plus additional sales revenue post-launch.
EBITDA margin for this NCE molecule is expected above 50%, showing strong profitability prospects.
The four-year exclusive manufacturing agreement with potential renewal for an additional four years provides a multi-year revenue runway.
The product targets a phosphate binder market worth over $1 billion, with global expansion plans beyond the U.S. over time.

Margin guidance

Shilpa Medicare's collaboration on the Oxylanthanum Carbonate (OLC) NCE molecule with Unicycive is expected to be a substantial revenue generator, with multimillion-dollar potential.
The company expects over 50% EBITDA margins from this exclusive CDMO supply contract.
Binding supply agreements involve supply of 5 million tablets by June 2025 and 15 million by December 2025, extending multi-year commercial supplies likely increasing revenues over several years.
$10 million cumulative milestone payments are expected, mostly before NDA approval, followed by ongoing sales revenue post launch.
The agreement is for four years, with automatic renewal for four more years, indicating a long runway for revenue and profit growth.
Pricing details are confidential, but favorable NCE exclusivity (likely 10+ years) and global manufacturing rights are expected to help sustain earnings.
Dedicated API manufacturing capacity expansion funded by the innovator ($6.5 million capex) supports expected volume growth for 2-3 years.

See what Shilpa Medicare Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention in the transcript about any current or future fundraising through debt or equity.
The discussion primarily focuses on the $6.5 million capex funding for the dedicated API block, which is entirely funded by the innovator (Unicycive) with no financial outlay from Shilpa Medicare.
No additional plans for capital raising through equity or debt are discussed during the call.
The company appears focused on executing the existing manufacturing and supply agreements, along with milestone and licensing revenue.

Order book

Yes

Unicycive has placed binding orders of 5 million tablets to be delivered before June 2025 and 15 million tablets before December 2025.
The binding agreement with Unicycive is for a term of four years, with multi-million tablet volumes expected each year beyond initial orders.
For tail supply, there is an order of 15 million tablets to be supplied before December.
The dedicated API manufacturing plant funded by Unicycive will suffice supply requirements for the next 2-3 years.
Currently, supply is ongoing from existing blocks while a dedicated manufacturing block is being built, expected to be ready in about one year.
There are no other near-commercialization projects besides OLC at present.

See what Shilpa Medicare Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Shilpa Medicare is setting up a dedicated API manufacturing block funded by their client (Unicycive Therapeutics) with a capex of approximately $6.5 million.
This dedicated block is being created to ensure supply does not hamper existing deliveries and will be ready within the next year.
The client is fully funding this capex; Shilpa is not contributing to this investment.
The dedicated block will have capacity sufficient for supply requirements over the next 2-3 years.
The funding and dedicated capacity demonstrate the strategic importance of this product and project to Shilpa.
No additional strategic or capital investments were specifically mentioned beyond this API block’s capex during the call.

Track Shilpa Medicare Ltd — get its next earnings analysis in your feed

How does Shilpa Medicare Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisShilpa Medicare Ltd

Rev 2

See where Shilpa Medicare Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Shilpa Medicare Ltd rank in Pharmaceuticals & Biotechnology?

Compare Shilpa Medicare Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Shilpa Medicare Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →